NCT01102387View on ClinicalTrials.gov

Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections

PHASE2CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Candidiasis
Interventions
DRUG

LAS41003

Once daily, topically

DRUG

LAS189962

Once daily, topically

DRUG

LAS189961

Once daily, topically

Trial Locations (6)

10961

Investigational Site #2, Berlin

15526

Investigational Site #4, Bad Saarow

20095

Investigational Site #1, Hamburg

48249

Investigational Site #6, Dülmen

49377

Investigational Site #3, Vechta

86179

Investigational Site #5, Augsburg

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
lead

Almirall, S.A.

INDUSTRY